MEDIF - Canadian CBD-Focused Pharma Co. Gets Green Light To Produce Medical Marijuana In Brazil | Benzinga
MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) has received a GMP certification for its Barrie, Ontario facility from ANVISA, the governing body of Brazil’s pharmaceutical industry.
This is MediPharm's latest approval, following GMP certifications from the FDA, European Union and Australia’s TGA, MediPharm also holds a drug establishment license from Health Canada.
The Toronto-based company is now positioned to produce both API and end products for Brazilian medical cannabis patients.
According to a 2023 report by industry observer Kaya Mind, the Brazilian medical cannabis market is projected to reach CA$380 million ($281.2 million) in 2025.
See also: New CBD & THC Cannabis Oils Now Shipping To Australia From Canada
“This GMP certification from Brazil ...